Treatment of leishmanial diseases involves systemic or local use of pentavalent antimony compounds and aromatic diamidines. The most used compounds are the two pentavalent antimonials, sodium stibogluconate (Pentostam) and meglumine antimoniate (Glucantime), which were first used in 1947 and 1950.